KR900701311A - 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법 - Google Patents
재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법Info
- Publication number
- KR900701311A KR900701311A KR1019900701665A KR900701665A KR900701311A KR 900701311 A KR900701311 A KR 900701311A KR 1019900701665 A KR1019900701665 A KR 1019900701665A KR 900701665 A KR900701665 A KR 900701665A KR 900701311 A KR900701311 A KR 900701311A
- Authority
- KR
- South Korea
- Prior art keywords
- interferon
- recombinant human
- squamous cell
- cell carcinoma
- intralesionally
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (8)
- 치료를 요하는 사람에게 항-편평세포 암제로서 유효한 충분량의 재조합 사람 α-2인터페론을 병소내 투여함을 특징으로 하는 사람 편평세포 암을 치료하는 방법.
- 제1항에 있어서, α-2인터페론이 재조합 사람 인터페론 α-2b인 방법.
- 제1항 또는 제2항에 있어서, 매회 주입량으로 0.1 내지 10*106국제단위의 재조합 사람 α-2 인터페론을 투여하여 치료하는 방법.
- 제1항, 제2항 및 제3항중 어느 한 항에 있어서, 주입용량이 1.5*106국제단위인 방법
- 제1항, 제2항, 제3항 및 제4항중 어느 한 항에 있어서, 주입용량이 1.5*106국제단위를 주당 3일씩 3주간 투여하는 방법.
- 편평세포 암의 병소내적 치료용 약제를 제조하기 위한 재조합 사람 α-2 인터페론의 용도.
- 편평세포 암을 병소내적으로 치료하기 위한 재조합 사람 α-2인터페론의 용도.
- 편평세포암을 병소내적으로 치료하는데 사용하기 위한 재조합 사람 α-2인터페론을 함유하는 약학적 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27831588A | 1988-12-01 | 1988-12-01 | |
US278,315 | 1988-12-01 | ||
US88-278,315 | 1988-12-01 | ||
PCT/US1989/005287 WO1990006135A1 (en) | 1988-12-01 | 1989-11-29 | Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon |
Publications (2)
Publication Number | Publication Date |
---|---|
KR900701311A true KR900701311A (ko) | 1990-12-01 |
KR950011889B1 KR950011889B1 (ko) | 1995-10-12 |
Family
ID=23064525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019900701665A KR950011889B1 (ko) | 1988-12-01 | 1989-11-29 | 정제된 재조합 사람 α-2 인터페론을 포함하는, 편평세포암 치료에 유용한 병소내 투여용 약제학적 조성물 |
Country Status (14)
Country | Link |
---|---|
EP (2) | EP0372809B1 (ko) |
JP (1) | JPH0647556B2 (ko) |
KR (1) | KR950011889B1 (ko) |
AT (1) | ATE92333T1 (ko) |
AU (1) | AU634511B2 (ko) |
CA (1) | CA2004202C (ko) |
DE (1) | DE68908119T2 (ko) |
DK (1) | DK103891D0 (ko) |
ES (1) | ES2058555T3 (ko) |
IE (1) | IE63121B1 (ko) |
IL (1) | IL92495A (ko) |
MY (1) | MY107071A (ko) |
WO (1) | WO1990006135A1 (ko) |
ZA (1) | ZA899113B (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992010207A1 (en) * | 1990-12-14 | 1992-06-25 | Schering Corporation | Oral administration of alpha interferon to treat lung malignancies |
IL100415A0 (en) * | 1990-12-21 | 1992-09-06 | Schering Corp | Administering alpha interferon by oral inhalation to treat asthma and non-malignant proliferative pulmonary diseases |
ATE229343T1 (de) * | 1995-10-04 | 2002-12-15 | Schering Corp | Kombination von temozolomide und alpha-interferon zur behandlung von fortgeschrittenem krebs |
US7294332B2 (en) | 1995-10-04 | 2007-11-13 | Schering Corporation | Combination therapy (temozolomide and α-IFN) for advanced cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3278234D1 (en) * | 1981-10-13 | 1988-04-21 | Exovir Inc | Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis |
PH26198A (en) * | 1986-05-27 | 1992-03-18 | Schering Corp | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon |
-
1989
- 1989-11-29 DE DE89312404T patent/DE68908119T2/de not_active Expired - Fee Related
- 1989-11-29 EP EP89312404A patent/EP0372809B1/en not_active Expired - Lifetime
- 1989-11-29 KR KR1019900701665A patent/KR950011889B1/ko not_active IP Right Cessation
- 1989-11-29 IL IL9249589A patent/IL92495A/en not_active IP Right Cessation
- 1989-11-29 AU AU48025/90A patent/AU634511B2/en not_active Ceased
- 1989-11-29 ES ES89312404T patent/ES2058555T3/es not_active Expired - Lifetime
- 1989-11-29 WO PCT/US1989/005287 patent/WO1990006135A1/en not_active Application Discontinuation
- 1989-11-29 CA CA002004202A patent/CA2004202C/en not_active Expired - Fee Related
- 1989-11-29 EP EP90900655A patent/EP0446279A1/en active Pending
- 1989-11-29 AT AT89312404T patent/ATE92333T1/de not_active IP Right Cessation
- 1989-11-29 ZA ZA899113A patent/ZA899113B/xx unknown
- 1989-11-29 MY MYPI89001661A patent/MY107071A/en unknown
- 1989-11-29 JP JP2501299A patent/JPH0647556B2/ja not_active Expired - Lifetime
- 1989-11-30 IE IE382889A patent/IE63121B1/en not_active IP Right Cessation
-
1991
- 1991-05-31 DK DK911038A patent/DK103891D0/da not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JPH04500678A (ja) | 1992-02-06 |
IL92495A (en) | 1995-05-26 |
ATE92333T1 (de) | 1993-08-15 |
IL92495A0 (en) | 1990-08-31 |
EP0372809B1 (en) | 1993-08-04 |
WO1990006135A1 (en) | 1990-06-14 |
AU634511B2 (en) | 1993-02-25 |
DK103891A (da) | 1991-05-31 |
IE63121B1 (en) | 1995-03-22 |
ES2058555T3 (es) | 1994-11-01 |
ZA899113B (en) | 1990-08-29 |
MY107071A (en) | 1995-09-30 |
AU4802590A (en) | 1990-06-26 |
EP0372809A1 (en) | 1990-06-13 |
KR950011889B1 (ko) | 1995-10-12 |
DE68908119T2 (de) | 1993-11-18 |
CA2004202C (en) | 2001-02-13 |
IE893828L (en) | 1990-06-01 |
CA2004202A1 (en) | 1990-06-01 |
EP0446279A1 (en) | 1991-09-18 |
DK103891D0 (da) | 1991-05-31 |
DE68908119D1 (de) | 1993-09-09 |
JPH0647556B2 (ja) | 1994-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT671910E (pt) | Utilizacao de derivados de adamantano no fabrico de um medicamento para o tratamento do glaucoma | |
DE69220808T2 (de) | Vorrichtung zur verabreichung von heilmitteln | |
ATE262920T1 (de) | Kontinuierliche, niedrigdosierte zytokine- infusionstherapie | |
MY117781A (en) | Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection | |
DE69333321D1 (de) | Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten. | |
DE69533112D1 (de) | Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken | |
PT710114E (pt) | Formulacao do factor viii de coagulacao | |
KR950703353A (ko) | 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus) | |
KR910700069A (ko) | Gm-csf를 사용한 백혈구 기능장애의 치료 | |
KR910005858A (ko) | 지방산 요법 | |
DE68909267D1 (de) | Medikament zur Behandlung von fibrotischer Störung und antifibrotische Verbindung. | |
ATE76579T1 (de) | Interferon-zusammensetzungen. | |
KR900701311A (ko) | 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법 | |
KR900701309A (ko) | 액체 질소 및 재조합 DNA사람 α인터페론을 혼용하여 생식기우종을 치료하는 방법 | |
KR870010871A (ko) | 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법 | |
KR900701322A (ko) | 포도필린과 재조합 DNA인간 α인터페론의 배합물로 생식기 우췌를 치료하는 방법 | |
ES2168772T3 (es) | Uso de hormona del crecimiento en composiciones para el tratamiento de la resistencia del corazon a la insulina. | |
ATE83381T1 (de) | Verwendung von rekombiniertem menschlichem alpha- interferon zur herstellung eines arzneimittels zur behandlung des aids-virus. | |
KR900700156A (ko) | 개선된 방사선 치료법 | |
DE60125377D1 (de) | Behandlung von hepatitis c mit thymosin, interferon und ribavirin | |
KR920014480A (ko) | 기흉 치료용 제약 조성물을 제조하기 위한 인간 인터류킨 2의 활성을 갖는 폴리펩티드의 용도 | |
DE60121449D1 (de) | Behandlung von hepatitis c mit thymosin und pegyliertem interferon | |
ES2067418A1 (es) | Nueva aplicacion de la interleukina-1 beta recombinante humana en el campo de la oftalmologia. | |
KR900012628A (ko) | 감마 인터페론의 유효량을 함유하는 복강내 투여용 난소암 치료제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |